The treatment of cancer patients with autologous T cells expressing a chimeric antigen
receptor (CAR) is one of the most promising adoptive cellular therapy approaches …

Lentiviral vectors (LVs) are potent tools for the delivery of genes of interest into mammalian
cells and are now commonly utilised within the growing field of cell and gene therapy for the …

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …

Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies.
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment
option for individuals with B cell malignancies but have yet to achieve success in treating …

CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T
cell suppression at the tumor site. T regulatory (Treg) cells suppress the immune response …

Adoptive cell therapy with genetically modified T cells expressing a chimeric antigen
receptor (CAR) is a promising therapy for patients with B-cell acute lymphoblastic leukemia …

Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic
modality pursued at an increasing number of medical centers. This immunotherapeutic …

The concept of precision cell therapy targeting tumor-specific mutations is appealing but
requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of …

CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set
of leukemia patients. However, CAR T-cell therapy thus far has been largely restricted to …